OneThree Biotech was born out of the largest precision medicine institute in America with the purpose of decreasing the failure rate of bringing therapeutics to market using biology driven artificial intelligence. Our technology was built in a lab setting; allowing us to engineer our methodologies around real-world results. While working with major biotech and pharma partners; we’ve validated our predictions through work in target discovery, compound and combination therapy identification, toxicity prediction, biomarker selection, and much more. Our predictions have been validated with partners such as AstraZeneca, Jubilant, and more. For example, we predicted the top indication, and mechanism of action for Oncoceutics asset ONC201 which was subsequently validated in a Phase II trial.
